Early access to vonsetamig for serious conditions
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This program provides early access to an experimental medicine called vonsetamig for people with serious conditions who have no other treatment options. It is only available on a case-by-case basis through a special request process.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening disease.
- Standard treatments must have failed or not be suitable for you.
- No other treatment options can be available.
- You must be under the care of a doctor who can support your application.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a special access program that lets you try an experimental medicine called ubamatamab when no standard treatments are working. Because it is a compassionate-use program, it is only for people with few or no other options.
This program provides access to an investigational medication called eltrombopag for people with serious or life-threatening conditions who have no other good treatment options. It is only available through a doctor's formal request and is not part of a clinical trial.
This study tests a new drug called velinotamig for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not improved with standard treatments. The drug aims to help your body stop attacking its own blood cells, which may improve your blood counts and symptoms.
This program provides access to valemetostat, an investigational pill, for people with certain types of peripheral T-cell lymphoma (PTCL) that have not responded to or returned after at least two prior treatments. The goal is to see if it can help control the disease.
This program provides access to an experimental medicine called ianalumab for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. Your doctor must request this medicine for you, and the company (Novartis) will review each request individually.
This trial provides access to a CAR T-cell therapy (ide-cel) that was made for you but didn't meet commercial release standards. It's an expanded access program for patients who have no other options and are stable enough to receive the treatment.
Hear when a new Plasma Cell Mediated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.